or
Bookmark and Share
   
Document Number
US Patent 5399702
Issued Date
March 21, 1995
Link
Inventors
Map
Abstract
Compounds of the formula: ##STR1## wherein the substituents are as defined herein, and enantiomers, diastereomers, racemates and salts with pharmaceutically acceptable bases, antagonize LTD.sub.4 action and thus, are useful in treating bronchial asthma, pulmonary anaphylaxis, cystic fibrosis, chronic bronchitis, bronchiectasis, respiratory distress syndrome and pulmonary oedema.
Drawing
Cycloalkylthiazoles - US Patent 5399702 Drawing
Drawing from US Patent 5399702
Tags:
Description:
Amusing 0%
Clever 0%
Complex 0%
Efficient 0%
Historic 0%
Important 0%
Innovative 0%
Interesting 0%
Practical 0%
Simple 0%
Number of Claims:
4
Comments:
no comments yet
Owner
Published
March 21, 1995
Application Number
08/116,386
Filed
September 2, 1993
US Classification
548/119   548/201 548/202 548/204 548/205
Int'l Classification
C07D   277/00   (20060101)   C07D   277/30   (20060101)   C07D   277/24   (20060101)   C07D   277/22   (20060101)   C07D   277/28   (20060101)   C07D   277/56   (20060101)   C07F   9/00   (20060101)   C07F   9/6539   (20060101)  
Examiner
Assistant Examiner
Parent Case
This is a division of application Ser. No. 07/907,987, filed Jul. 2, 1992, now U.S. Pat. No. 5,273,986.
USPTO Field of Search
548/119   548/201   548/202   548/204   548/205  
Related Patents
7199140 - Vinyl phenyl derivatives as GLK activators - Owned by AstraZeneca AB (Sodertalje,SE)

The invention relates to novel compounds of Formula (I) or a salt, solvate or prodrug thereof, wherein A, R.sup.1, R.sup.2, R.sup.3, n and m are described in the specification, useful in the treatment of ##STR00001## a disease or condition mediated through glucokinase (GLK), such as type 2 diabetes. The invention also relates to methods for preparing compounds of Formula (I) and their use as medicaments in the treatment of diseases mediated by glucokinase.

7524957 - Compounds effecting glucokinase - Owned by AstraZeneca AB (Sodertalje,SE)

The invention relates to the use of a compound of Formula (I) or a salt, solvate or prodrug thereof, wherein R.sup.1, R.sup.2, R.sup.3, n and m are as described in the specification, in the preparation of a medicament for the treatment or prevention of a disease condition mediated through glucokinase (GLK), such as type 2 diabetes. ##STR00001## The invention also relates to a novel group of compounds of Formula (I) and to methods for preparing compounds of Formula (I).

Claims
Description
About| FAQs| Terms & Disclaimer| Link to Us| Contact Us